NeuBase Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview

NeuBase Therapeutics

13/08/2021 03:51

* NeuBase Therapeutics Inc  NBSE.OQ   NBSE.O  is expected
to show a no change in quarterly revenue when it reports
results on August 13 (estimated). 
​* Refinitiv's mean analyst estimate for NeuBase Therapeutics
Inc is for a loss of 21 cents per share. For the same quarter
last year, the company reported a loss of 18 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for NeuBase
Therapeutics Inc is $16.5​, about 79.1% above​ its last closing
price of $3.46. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.20       -0.22      -0.24     Missed  -9.1
 Dec. 31 2020  -0.23       -0.23      -0.18     Beat    21.7
 Sep. 30 2020              -0.20      -0.19     Beat    4.2​
 Jun. 30 2020  -0.23       -0.23      -0.18     Beat    20.6
 Mar.          -0.22​      -0.22      -0.26     Missed  -16.9​
 31​ 2020​                                              
 Dec. 31 2019  -0.37       -0.32      -0.26     Beat    18.1​
 Sep. 30 2019  -0.27       -0.28      -2.14     Missed  -673.5
 This summary was machine generated August 13 at 02:51 GMT.  All
figures in US dollars unless otherwise stated